The Effect of Suppression Taurine on Relocation and Epithelial-Mesenchymal Transition in Mankind Lung Cancer Cells

Deng, Yongyan; Li, Hongjin; Tang, Yujiao

doi:10.1155/2021/6656080

Cited by 8 publications

(7 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Natural compounds with antioxidant activity and low cytotoxicity give rise to a new era of research where they can cure and treat cancer and other associated diseases. Previous studies have reported that taurine can be used to treat cancer, , but the inhibition of expression and activity of CDK6 by taurine provides a novel avenue for cancer therapy.…”

Section: Introductionmentioning

confidence: 99%

Inhibiting Cyclin-Dependent Kinase 6 by Taurine: Implications in Anticancer Therapeutics

et al. 2022

View full text Add to dashboard Cite

Cyclin-dependent kinase 6 (CDK6) is linked with a cyclin partner and plays a crucial role in the early stages of cancer development. It is currently a potential drug target for developing therapeutic molecules targeting cancer therapy. Here, we have identified taurine as an inhibitor of CDK6 using combined in silico and experimental studies. We performed various experiments to find the binding affinity of taurine with CDK6. Molecular docking analysis revealed critical residues of CDK6 that are involved in taurine binding. Fluorescence measurement studies showed that taurine binds to CDK6 with a significant binding affinity, with a binding constant of K = 0.7 × 10 7 M –1 for the CDK6–taurine complex. Enzyme inhibition assay suggested taurine as a good inhibitor of CDK6 possessing an IC 50 value of 4.44 μM. Isothermal titration calorimetry analysis further confirmed a spontaneous binding of taurine with CDK6 and delineated the thermodynamic parameters for the CDK6–taurine system. Altogether, this study established taurine as a CDK6 inhibitor, providing a base for using taurine and its derivatives in CDK6-associated cancer and other diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Inhibiting Cyclin-Dependent Kinase 6 by Taurine: Implications in Anticancer Therapeutics

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Some previous metabolomic studies on thyroid nodules found that compared with benign nodules, the contents of lactic acid and taurine were increased in malignant thyroid nodules [ 39 , 42 , 44 ]. Taurine is believed to have antioxidant properties and has been implicated in the treatment of neurodegenerative disease, atherosclerosis, coronary heart disease, and prostate cancer [ 45 , 46 ]. It has also been found that taurine can inhibit tumor cell proliferation, enhance apoptosis, inhibit angiogenesis and play an anti-tumor role [ 47 ].…”

Section: Discussionmentioning

confidence: 99%

Experimental study on changes in metabolic mechanism of papillary thyroid carcinoma complicated with Hashimoto’s thyroiditis

Sun,

Zhang,

Wang

et al. 2023

Heliyon

View full text Add to dashboard Cite

“…Taurine, as conditionally essential amino acid of human, has multiple physiological functions, including the regulation of neural conduction, participating in endocrine activities, immunity enhancement, and strengthening the antioxidant capacity of cytomembrane ( 35 ). Taurine was found to inhibit the proliferation of lung cancer cells, significantly boosted the apoptosis rate, and reduced the expression of migration factors matrix metallopeptidase 9 (MMP-9) and vascular endothelial growth factor (VEGF) ( 36 , 37 ). Previous studies have shown that taurine ABC transporter protein has been identified in Lactobacillus , and this could have something to do with the enrichment of Lactobacillus in controls of our study ( 38 ).…”

Section: Discussionmentioning

confidence: 99%

Characterizing microbiota and metabolomics analysis to identify candidate biomarkers in lung cancer

Liu

Suo

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundLung cancer is the leading malignant disease and cause of cancer-related death worldwide. Most patients with lung cancer had insignificant early symptoms so that most of them were diagnosed at an advanced stage. In addition to factors such as smoking, pollution, lung microbiome and its metabolites play vital roles in the development of lung cancer. However, the interaction between lung microbiota and carcinogenesis is lack of systematically characterized and controversial. Therefore, the purpose of this study was to excavate the features of the lung microbiota and metabolites in patients and verify potential biomarkers for lung cancer diagnosis.MethodsLung tissue flushing solutions and bronchoalveolar lavage fluid samples came from patients with lung cancer and non-lung cancer. The composition and variations of the microbiota and metabolites in samples were explored using muti-omics technologies including 16S rRNA amplicon sequencing, metagenomics and metabolomics.ResultsThe metabolomics analysis indicated that 40 different metabolites, such as 9,10-DHOME, sphingosine, and cysteinyl-valine, were statistically significant between two groups (VIP > 1 and P < 0.05). These metabolites were significantly enriched into 11 signal pathways including sphingolipid, autophagy and apoptosis signaling pathway (P < 0.05). The analysis of lung microbiota showed that significant changes reflected the decrease of microbial diversity, changes of distribution of microbial taxa, and variability of the correlation networks of lung microbiota in lung cancer patients. In particular, we found that oral commensal microbiota and multiple probiotics might be connected with the occurrence and progression of lung cancer. Moreover, our study found 3 metabolites and 9 species with significantly differences, which might be regarded as the potential clinical diagnostic markers associated with lung cancer.ConclusionsLung microbiota and metabolites might play important roles in the pathogenesis of lung cancer, and the altered metabolites and microbiota might have the potential to be clinical diagnostic markers and therapeutic targets associated with lung cancer.

show abstract

The Effect of Suppression Taurine on Relocation and Epithelial-Mesenchymal Transition in Mankind Lung Cancer Cells

Cited by 8 publications

References 39 publications

Inhibiting Cyclin-Dependent Kinase 6 by Taurine: Implications in Anticancer Therapeutics

Inhibiting Cyclin-Dependent Kinase 6 by Taurine: Implications in Anticancer Therapeutics

Experimental study on changes in metabolic mechanism of papillary thyroid carcinoma complicated with Hashimoto’s thyroiditis

Characterizing microbiota and metabolomics analysis to identify candidate biomarkers in lung cancer

Contact Info

Product

Resources

About